Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $220.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sumant Kulkarni has given his Buy rating due to a combination of factors related to Biogen’s strategic initiatives and promising pipeline developments. A significant aspect of this rating is Biogen’s acquisition of felzartamab, a product with potential in treating rare kidney diseases, which the company plans to explore through multiple Phase 3 trials. The unmet need in these areas presents commercially attractive opportunities, and the early promise of felzartamab indicates it could become a substantial revenue driver by 2028 and beyond.
Additionally, Biogen’s efforts to expand its immunology franchise, including the development of dapirolizumab pegol for lupus, demonstrate a strategic move to diversify beyond its traditional focus on neurology. This diversification reduces the risk associated with high-stakes pipeline bets. Furthermore, the continued importance of Leqembi for early Alzheimer’s disease, especially with potential advancements in subcutaneous dosing, reinforces Biogen’s potential for top-line growth. These factors, combined with upcoming pipeline catalysts, contribute to Kulkarni’s positive outlook and Buy rating for Biogen.
In another report released on June 12, H.C. Wainwright also maintained a Buy rating on the stock with a $187.00 price target.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BIIB in relation to earlier this year.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue